AIM ImmunoTech Wins U.S. Patent for Ampligen Cancer Therapy
OCALA, Fla., August 31, 2026 AIM ImmunoTech Inc. announced that the U.S. Patent and Trademark Office (USPTO) has granted...
KEYTRUDA
Advertisement
Merck and Moderna Report Phase 3 Melanoma Success
Rahway, New Jersey, and Cambridge, Massachusetts, August 19, 2026 Merck and Moderna announced positive topline results from the Phase...
BioInvent Receives FDA Fast Track Designation for BI-1808
LUND, Sweden, August 7, 2026 BioInvent International AB announced that the U.S. Food and Drug Administration (FDA) has granted...
Gilead Sciences Secures CHMP Support for Trodelvy Plus KEYTRUDA
FOSTER CITY, Calif., July 24, 2026 Gilead Sciences announced that the European Medicines Agency’s Committee for Medicinal Products for...
Alpha Tau Medical Ltd. Reports Positive Head and Neck Cancer Results
JERUSALEM, July 21, 2026 Alpha Tau Medical Ltd. announced positive clinical study results evaluating its Alpha DaRT® (Diffusing Alpha-emitters...
Advertisements
Almirall Seeks EMA Approval to Expand Ebglyss Use in Kids
BARCELONA, Spain, July 17, 2026 Almirall S.A. has announced that the European Medicines Agency (EMA) has accepted the Marketing...
Marengo Earns ESMO Oral Slot for Phase II Cancer Data
CAMBRIDGE, Mass., July 20, 2026 Marengo Therapeutics has announced that updated Phase II clinical data from its investigational immunotherapy...
Evaxion Highlights Phase 2 EVX-01 Melanoma Results
Copenhagen, Denmark, July 17, 2026 Evaxion A/S announced that it will present three-year clinical efficacy data from its Phase...
Kelun-Biotech Reports Phase III Success for sac-TMT in NSCLC
CHENGDU, China, July 14, 2026 Kelun-Biotech has announced a major clinical milestone after its Phase III OptiTROP-Lung06 trial evaluating...
Immutep Reports Positive INSIGHT-003 Survival Data
SYDNEY, Australia, July 13, 2026 Immutep announced positive mature overall survival data from its investigator-initiated Phase 1 INSIGHT-003 trial...
Advertisement
